Efficacy and safety of alternate-day prednisolone compared to single daily cloprednol were evaluated over a six-week period in 11 children with severe asthma requiring in-residence medical supervision and long-term corticosteroid therapy. Clinical indices of efficacy, including daily pulmonary symptom scores, number of asthma attacks, asthma severity scores, and bronchodilator usage, all favored cloprednol. Afternoon pulmonary function tests (FEV1, FVC, and PEFR) were all significantly improved during the cloprednol period. Although plasma cortisol values remained within the broad range of normal during the cloprednol period, mean values were consistent with partial pituitary-adrenal suppression similar in degree to that observed 24 hours after administration of an alternate-day program of prednisolone therapy. The results of this trial showed cloprednol in single daily doses to be more effective than prednisolone in alternate doses for the treatment of children with severe asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/j.1552-4604.1979.tb01631.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Memory enhancement by transcranial radiofrequency wave treatment occurs without appreciably increasing brain temperature.
Phys Eng Sci Med
January 2025
RF Longevity, 428 E. Thunderbird Road, Phoenix, SE, AZ, 85022, USA.
We have previously shown in small studies that full brain Transcranial Radiofrequency Wave Treatment (TRFT) to subjects with Alzheimer's Disease could stop and reverse their cognitive decline. An 8-emitter head device, the "MemorEM", was used in these studies to provide TRFT at 915 MHz frequency and power level of 1.6 W/kg Specific Absorption Rate (SAR) during daily 1-hour treatments.
View Article and Find Full Text PDFNon-linear oral bioavailability and clinical pharmacokinetics of high-dose ethanolic extract: relevant dosage implications for COVID-19 treatment.
Pharm Biol
December 2025
Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
Aim: Insufficient quality control and limited dissolution of extract capsules restricts their bioavailability and hinder the clinical use for treating mild coronavirus disease 2019 (COVID-19) patients.
Objective: This study aims to investigate pharmacokinetics and safety of high-dosage ethanolic extract (equivalent to 180 or 360 mg/day of andrographolide), relevant dosages used for mild COVID-19 treatment.
Methods: An open-label, single-dose, and repeated-dose conducted in healthy volunteers.
Effect of differences in residual feed intake on gastrointestinal microbiota of Dexin fine-wool meat sheep.
Front Microbiol
December 2024
Xinjiang Academy of Animal Husbandry Sciences, Urumqi, China.
In this study, we examined the effects of different residual feed intakes (RFIs) on nutrient digestibility and the microbiota of the digestive tract of Dexin fine-wool sheep. Fifty 70-day-old Dexin fine-wool meat lambs were selected as the experimental group and fed in a single pen for 100 days. Based on their mid-term metabolic weight, 100-day average daily weight gain and daily feed intake, the male Dexin lambs were divided into a low-RFI group (13), a mid-RFI group (18), and a high-RFI group (11).
View Article and Find Full Text PDFDevelopment and feasibility testing of a new device for home-based leg heat therapy in patients with lower extremity peripheral artery disease.
J Vasc Surg Cases Innov Tech
February 2025
Department of Health and Kinesiology, Purdue University, West Lafayette, IN.
People with symptomatic lower extremity peripheral artery disease (PAD) suffer from severe leg pain, walking impairment, and reduced quality of life, but few effective treatments are available. Emerging evidence suggests that regular heat therapy (HT) may improve cardiovascular and physical function in patients with PAD. However, the lack of accessible, practical modalities for unsupervised HT, especially for elderly individuals, has hindered clinical implementation.
View Article and Find Full Text PDFEfficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.
Ther Adv Med Oncol
January 2025
Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, China.
Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations.
Objectives: This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!